Literature DB >> 6232336

Generation and decay of the immune response to a progressive fibrosarcoma. II. Failure to demonstrate postexcision immunity after the onset of T cell-mediated suppression of immunity.

I Bursuker, R J North.   

Abstract

This study shows that surgical removal of the meth A fibrosarcoma from its semisyngeneic host fails to result in postexcision immunity to growth of a tumor implant unless the host already has acquired a mechanism of concomitant immunity to growth of an implant. Therefore, tumor excision does not cause immunity to be generated but preserves a mechanism of concomitant immunity that already exists and which otherwise would eventually undergo down-regulation under the influence of suppressor T cells. Removal of the tumor after it has grown large enough to cause the T cell-mediated suppression of concomitant immunity does not result in the reemergence of immunity. Instead, the host remains unable to generate concomitant immunity to a second tumor for a long period of time and retains, for at least 31 d, suppressor T cells able to passively transfer suppression to appropriate recipients. Like the suppressor T cells responsible for active suppression of concomitant immunity, the suppressor T cells responsible for "memory" suppression are of the Ly-1+2- phenotype. The results indicate that progressive tumor growth results in a state of immunological tolerance of tumor-specific, transplantation antigens that can persist in the apparent absence of tumor antigens.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6232336      PMCID: PMC2187291          DOI: 10.1084/jem.159.5.1312

Source DB:  PubMed          Journal:  J Exp Med        ISSN: 0022-1007            Impact factor:   14.307


  13 in total

Review 1.  IMMUNOLOGY OF EXPERIMENTAL TUMORS.

Authors:  L J OLD; E A BOYSE
Journal:  Annu Rev Med       Date:  1964       Impact factor: 13.739

2.  IMMUNITY TO SPONTANEOUS AND METHYLCHOLANTHRENE-INDUCED TUMORS IN INBRED MICE.

Authors:  R S RIGGINS; Y H PILCH
Journal:  Cancer Res       Date:  1964-12       Impact factor: 12.701

3.  Immunity to methylcholanthrene-induced sarcomas.

Authors:  R T PREHN; J M MAIN
Journal:  J Natl Cancer Inst       Date:  1957-06       Impact factor: 13.506

4.  Antigenic properties of methylcholanthrene-induced tumors in mice of the strain of origin.

Authors:  E J FOLEY
Journal:  Cancer Res       Date:  1953-12       Impact factor: 12.701

Review 5.  The involvement of activated specific suppressor T cells in maintenance of transplantation tolerance.

Authors:  I Hilgert
Journal:  Immunol Rev       Date:  1979       Impact factor: 12.988

Review 6.  Complexity of the state of immunological tolerance.

Authors:  M Hasek; J Chutná
Journal:  Immunol Rev       Date:  1979       Impact factor: 12.988

Review 7.  Transplantation methods as a tool for detection of tumor-specific antigens.

Authors:  H O Sjögren
Journal:  Prog Exp Tumor Res       Date:  1965

Review 8.  Concomitant tumor immunity and the resistance to a second tumor challenge.

Authors:  E Gorelik
Journal:  Adv Cancer Res       Date:  1983       Impact factor: 6.242

9.  T cell-mediated immunosuppression as an obstacle to adoptive immunotherapy of the P815 mastocytoma and its metastases.

Authors:  E S Dye; R J North
Journal:  J Exp Med       Date:  1981-10-01       Impact factor: 14.307

10.  Generation and decay of the immune response to a progressive fibrosarcoma. I. Ly-1+2- suppressor T cells down-regulate the generation of Ly-1-2+ effector T cells.

Authors:  R J North; I Bursuker
Journal:  J Exp Med       Date:  1984-05-01       Impact factor: 14.307

View more
  23 in total

1.  Cyclophosphamide enhances immunity by modulating the balance of dendritic cell subsets in lymphoid organs.

Authors:  Takeshi Nakahara; Hiroshi Uchi; Alexander M Lesokhin; Francesca Avogadri; Gabrielle A Rizzuto; Daniel Hirschhorn-Cymerman; Katherine S Panageas; Taha Merghoub; Jedd D Wolchok; Alan N Houghton
Journal:  Blood       Date:  2010-02-12       Impact factor: 22.113

Review 2.  The battle against immunopathology: infectious tolerance mediated by regulatory T cells.

Authors:  David M Gravano; Dario A A Vignali
Journal:  Cell Mol Life Sci       Date:  2011-12-29       Impact factor: 9.261

3.  A positive-margin resection model recreates the postsurgical tumor microenvironment and is a reliable model for adjuvant therapy evaluation.

Authors:  Jarrod D Predina; Brendan Judy; Zvi G Fridlender; Louis A Aliperti; Brian Madajewski; Veena Kapoor; Guanjun Cheng; Jon Quatromoni; Olugbenga Okusanya; Sunil Singhal
Journal:  Cancer Biol Ther       Date:  2012-05-23       Impact factor: 4.742

4.  Adjuvant therapy with agonistic antibodies to CD134 (OX40) increases local control after surgical or radiation therapy of cancer in mice.

Authors:  Michael J Gough; Marka R Crittenden; MaryClare Sarff; Puiyi Pang; Steven K Seung; John T Vetto; Hong-Ming Hu; William L Redmond; John Holland; Andrew D Weinberg
Journal:  J Immunother       Date:  2010-10       Impact factor: 4.456

5.  Mechanisms of tumor-induced immunosuppression: evidence for contact-dependent T cell suppression by monocytes.

Authors:  M L Jaffe; H Arai; G J Nabel
Journal:  Mol Med       Date:  1996-11       Impact factor: 6.354

Review 6.  FOXP3+ Tregs: heterogeneous phenotypes and conflicting impacts on survival outcomes in patients with colorectal cancer.

Authors:  Changhua Zhuo; Ye Xu; Mingang Ying; Qingguo Li; Liyong Huang; Dawei Li; Sanjun Cai; Bin Li
Journal:  Immunol Res       Date:  2015-03       Impact factor: 2.829

Review 7.  Tregs and rethinking cancer immunotherapy.

Authors:  Tyler J Curiel
Journal:  J Clin Invest       Date:  2007-05       Impact factor: 14.808

8.  Suppression of generation of concomitant antitumor immunity by passively transferred suppressor T cells from tumor-bearing donors.

Authors:  I Bursuker; R J North
Journal:  Cancer Immunol Immunother       Date:  1985       Impact factor: 6.968

9.  Induction of postsurgical tumor immunity and T-cell memory by a poorly immunogenic tumor.

Authors:  Peisheng Zhang; Anik L Côté; Victor C de Vries; Edward J Usherwood; Mary Jo Turk
Journal:  Cancer Res       Date:  2007-07-01       Impact factor: 12.701

10.  Targeting macrophages in the tumour environment to enhance the efficacy of αOX40 therapy.

Authors:  Michael J Gough; N Killeen; Andrew D Weinberg
Journal:  Immunology       Date:  2012-08       Impact factor: 7.397

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.